MARKET

AYTU

AYTU

Aytu Biopharma Inc
NASDAQ
2.890
+0.020
+0.70%
Closed 16:00 03/18 EDT
OPEN
2.820
PREV CLOSE
2.870
HIGH
3.180
LOW
2.820
VOLUME
62.25K
TURNOVER
0
52 WEEK HIGH
3.500
52 WEEK LOW
1.380
MARKET CAP
16.09M
P/E (TTM)
-0.7122
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AYTU last week (0311-0315)?
Weekly Report · 18h ago
Weekly Report: what happened at AYTU last week (0304-0308)?
Weekly Report · 03/11 12:24
Weekly Report: what happened at AYTU last week (0226-0301)?
Weekly Report · 03/04 12:29
Weekly Report: what happened at AYTU last week (0219-0223)?
Weekly Report · 02/26 12:50
Weekly Report: what happened at AYTU last week (0212-0216)?
Weekly Report · 02/19 12:52
Maxim Group Remains a Buy on Aytu BioScience (AYTU)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Aytu BioScience yesterday. The company’s shares closed yesterday at $3.12. Rahman covers the Healthcare sector and has an average return of -10.1%. The company reported a quarterly revenue of $22.1 million.
TipRanks · 02/16 12:57
Aytu BioScience GAAP EPS of -$0.04 beats by $0.21, revenue of $22.93M beats by $1.18M
Seeking Alpha · 02/14 21:20
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma reported quarterly losses of $0.04 per share. The company also reported quarterly sales of $22.93 million. This is a 12.73 percent decrease over sales of the same period last year. Aytu beat the analyst consensus estimate by 84 percent.
Benzinga · 02/14 21:16
More
About AYTU
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

Webull offers Aytu Biopharma Inc stock information, including NASDAQ: AYTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AYTU stock methods without spending real money on the virtual paper trading platform.